{"name":"Stallergenes Greer","slug":"stallergenes","ticker":"Private","exchange":"Private (subsidiary of Ares Life Sciences)","domain":"stallergenesgreer.com","description":"Stallergenes Greer International AG is a Swiss biopharmaceutical company specializing in the diagnosis and treatment of allergies through allergen immunotherapy.","hq":"Antony, France","founded":0,"employees":"","ceo":"Michele Antonelli","sector":"Allergy / Immunotherapy","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private (~€1.5B est.)","metrics":{"revenue":520000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Staloral patent cliff ($100M at risk)","drug":"Staloral","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"300 IR","genericName":"300 IR","slug":"300-ir","indication":"Other","status":"marketed"},{"name":"Oralair","genericName":"Oralair","slug":"oralair","indication":"Other","status":"marketed"},{"name":"Staloral","genericName":"Staloral","slug":"staloral","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"300 IR","genericName":"300 IR","slug":"300-ir","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Oralair","genericName":"Oralair","slug":"oralair","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Staloral","genericName":"Staloral","slug":"staloral","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-09-07","type":"deal","headline":"Stallergenes Greer Acquires Greer Laboratories","summary":"Stallergenes Greer acquired Greer Laboratories, expanding its presence in the allergy and immunotherapy market.","drugName":"","sentiment":"positive"},{"date":"2022-02-22","type":"regulatory","headline":"Stallergenes Greer Receives FDA Approval for Oral Allergy Immunotherapy","summary":"Stallergenes Greer received FDA approval for its oral allergy immunotherapy treatment, marking a significant milestone for the company.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPY3lEMUVXSGprci1qZHMtV0lqOWV5ajJtcHU4VmVBTTFPdS1lTmd5bWlzNDVVQWNUQURFNUJlR3g4WHNRZGdTaVhVSFN4S3RFUnhKQTFyZ0VkRDZTSERsS2R2SHJoQTYtVUNnWUhaSWFidGcyWXVYd1lnd1Bya1pqQVBTRVBYOHhkaVFQT2w2WDJLN1QxUkFwQjB1OTdONjBzQVlqdkdkbmo0bFdjQ2R6ZGo0Q2lZY0lpdF9N?oc=5","date":"2023-09-05","type":"pipeline","source":"Pharmaceutical Technology","summary":"Nestlé divests peanut allergy treatment Palforzia to Stallergenes Greer - Pharmaceutical Technology","headline":"Nestlé divests peanut allergy treatment Palforzia to Stallergenes Greer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNSndUS0ZyMmNmaUxxTDRILXd1VVczcmt1cHNiNlpueGU2LXVFWFVTTG9mME9TUDdTaEViOXgxYXR5SE5qd3BaU3VRN04yX09VaTRwVGZoRlgzLWRWODFmcktGWGZIT19iWUdHdV9LTnlxZ0ZEOWhlN2Ffd1U4TjluMWtSclZxUEFBaXN5bWUwc2NOdEZtOTRKNDlGb0NFcXQxakg5Ykc0R1VPLUhtSXRtcVlnVTI?oc=5","date":"2019-03-21","type":"pipeline","source":"Bloomberg.com","summary":"Switzerland's Richest Man Takes Drugmaker Private at 43% Premium - Bloomberg.com","headline":"Switzerland's Richest Man Takes Drugmaker Private at 43% Premium","sentiment":"neutral"}],"patents":[{"drugName":"Staloral","drugSlug":"oral-allergy-immunotherapy","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000}],"drugCount":3,"phaseCounts":{"marketed":2,"phase_3":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Allergan","Merck & Co.","Regeneron Pharmaceuticals"],"therapeuticFocus":["Allergy","Immunotherapy"],"financials":null,"yahoo":null}